Figure 5. BrdU administration reveals high monocyte turnover following LA treatment.

Rh28438 and Rh29054 received 10 mg/kg LA i.v., along with 60 mg/kg BrdU i.v. Control animal Rh31577 received PBS along with the same 60-mg/kg dose of BrdU. LA treatment depleted the majority of blood monocytes based on: (A) frequency assessed by CD45 staining versus side-scatter profile and (B) absolute monocyte counts. (C) BrdU staining revealed high levels of monocyte turnover following LA treatment in both the CD14⁺CD16⁻ (classical) and CD14⁺CD16⁺ (intermediate) monocyte populations. Values shown indicate percent of total CD14⁺CD16⁻ (classical) and CD14⁺CD16⁺ (intermediate) populations staining positive for BrdU.